This patent teaches the novel use of melanoma inhibitory factor to induce stem cell differentiation into bone and cartilage. It may be used for in vitro generation of stem cells or for acceleration of in vivo healing. The independent claims of the patent are:
A method for inducing chondro-/ostrogenic lineage and promoting of cartilage or bone formation in a person comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and at least one biocompatible or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic-coglycolid, polyanhydrides and collagen to a person in need thereof.
A pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, in combination with an osteoinductive protein, wherein said osteoinductive protein is selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein.
A method for inducing chondro-/ostrogenic lineage and promoting of cartilage or bone formation in a person comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and at least one biocompatible and/or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic-coglycolid, polyanhydrides and collagen, wherein the biocompatible matrix is at least one member selected from the group consisting of hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and polyactic-coglycolid derivatives.
A method of inducting of the chondro-/osteogenic lineage and promoting cartilage and/or bone formation comprising administering an effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, at least one biocompatible or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides and collagen, and an osteoinductive protein selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein to a subject.
A method of treating or repairing at least one of bone or cartilage in a patient comprising administering to a patient in need of bone or cartilage treatment or repair, an effective amount of a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, to the patient to repair the bone or cartilage.
A pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and a biocompatible matrix, wherein said biocompatible matrix is a three dimensional sponge prepared from collagen, alginate, tricalcium phosphate, and hydroxyapatite.
A method of treating or repairing at least one of bone or cartilage in a patient comprising administering an effective amount of a composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and an osteoinductive protein to the patient to repair the bone or cartilage.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.